Agilus top-line growth remains sluggish
Agilus revenue grew only 3.4% YoY, trailing peers, due to brand transition impact and low-value PPP business decline. Recovery to double-digit growth is uncertain.
FORTIS / Q2-FY25 / risks
Keep the risk register visible.
Fortis Healthcare · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Brownfield ramp-up may pressure near-term margins
New bed additions at Manesar and other facilities are expected to initially drag EBITDA, with Manesar break-even estimated at 15 months.
Legal costs remain elevated
Legal costs related to ongoing High Court cases are higher this year due to increased hearings, with no immediate resolution expected.
Seasonal occupancy dip in Q3
Festival season typically reduces occupancy in Q3, which could impact sequential revenue and margin performance.